D
Rocket Pharmaceuticals, Inc.
RCKT
$8.32
-$0.14-1.66%
D
Sell
12/13/2024Upgraded
Rocket Pharmaceuticals, Inc. (RCKT) was upgraded to D- from E+ on 12/13/2024 due to an increase in the growth index and valuation index. EBIT increased 5.82% from -$73.71M to -$69.42M, earnings per share increased from -$0.7429 to -$0.7086, and operating cash flow increased 3.2% from -$53.82M to -$52.1M.
Rocket Pharmaceuticals, Inc. (RCKT) was upgraded to D- from E+ on 12/13/2024 due to an increase in the growth index and valuation index. EBIT increased 5.82% from -$73.71M to -$69.42M, earnings per share increased from -$0.7429 to -$0.7086, and operating cash flow increased 3.2% from -$53.82M to -$52.1M.
E
Sell
6/13/2024Downgrade
Rocket Pharmaceuticals, Inc. (RCKT) was downgraded to E+ from D- on 6/13/2024 due to a decline in the valuation index.
Rocket Pharmaceuticals, Inc. (RCKT) was downgraded to E+ from D- on 6/13/2024 due to a decline in the valuation index.
D
Sell
10/10/2023Upgraded
Rocket Pharmaceuticals, Inc. (RCKT) was upgraded to D- from E+ on 10/10/2023 due to an increase in the valuation index.
Rocket Pharmaceuticals, Inc. (RCKT) was upgraded to D- from E+ on 10/10/2023 due to an increase in the valuation index.
E
Sell
9/21/2023Downgrade
Rocket Pharmaceuticals, Inc. (RCKT) was downgraded to E+ from D- on 9/21/2023 due to a decline in the volatility index, solvency index and valuation index. The quick ratio declined from 10.61 to 8.94.
Rocket Pharmaceuticals, Inc. (RCKT) was downgraded to E+ from D- on 9/21/2023 due to a decline in the volatility index, solvency index and valuation index. The quick ratio declined from 10.61 to 8.94.
D
Sell
3/20/2023Downgrade
Rocket Pharmaceuticals, Inc. (RCKT) was downgraded to D- from D on 03/20/2023.
Rocket Pharmaceuticals, Inc. (RCKT) was downgraded to D- from D on 03/20/2023.
D
Sell
3/3/2023Upgraded
Rocket Pharmaceuticals, Inc. (RCKT) was upgraded to D from D- on 3/3/2023 due to an increase in the solvency index, valuation index and total return index.
Rocket Pharmaceuticals, Inc. (RCKT) was upgraded to D from D- on 3/3/2023 due to an increase in the solvency index, valuation index and total return index.
D
Sell
2/1/2023Downgrade
Rocket Pharmaceuticals, Inc. (RCKT) was downgraded to D- from D on 2/1/2023 due to a decline in the total return index, valuation index and solvency index. The quick ratio declined from 13.23 to 10.16.
Rocket Pharmaceuticals, Inc. (RCKT) was downgraded to D- from D on 2/1/2023 due to a decline in the total return index, valuation index and solvency index. The quick ratio declined from 13.23 to 10.16.
D
Sell
10/6/2022Upgraded
Rocket Pharmaceuticals, Inc. (RCKT) was upgraded to D from D- on 10/6/2022 due to an increase in the volatility index and total return index.
Rocket Pharmaceuticals, Inc. (RCKT) was upgraded to D from D- on 10/6/2022 due to an increase in the volatility index and total return index.
D
Sell
9/21/2022Downgrade
Rocket Pharmaceuticals, Inc. (RCKT) was downgraded to D- from D on 9/21/2022 due to a decline in the volatility index.
Rocket Pharmaceuticals, Inc. (RCKT) was downgraded to D- from D on 9/21/2022 due to a decline in the volatility index.
D
Sell
9/1/2022Upgraded
Rocket Pharmaceuticals, Inc. (RCKT) was upgraded to D from D- on 9/1/2022 due to an increase in the total return index.
Rocket Pharmaceuticals, Inc. (RCKT) was upgraded to D from D- on 9/1/2022 due to an increase in the total return index.
D
Sell
4/20/2022Downgrade
Rocket Pharmaceuticals, Inc. (RCKT) was downgraded to D- from D on 4/20/2022 due to a large decline in the total return index and solvency index.
Rocket Pharmaceuticals, Inc. (RCKT) was downgraded to D- from D on 4/20/2022 due to a large decline in the total return index and solvency index.
D
Sell
11/23/2021Upgraded
Rocket Pharmaceuticals, Inc. (RCKT) was upgraded to D from D- on 11/23/2021 due to an increase in the valuation index and total return index.
Rocket Pharmaceuticals, Inc. (RCKT) was upgraded to D from D- on 11/23/2021 due to an increase in the valuation index and total return index.
D
Sell
11/8/2021Downgrade
Rocket Pharmaceuticals, Inc. (RCKT) was downgraded to D- from D on 11/8/2021 due to a large decline in the growth index, efficiency index and valuation index. EBIT declined 45.81% from -$34.05M to -$49.65M, net income declined 45.16% from -$34.53M to -$50.12M, and earnings per share declined from -$0.5475 to -$0.7852.
Rocket Pharmaceuticals, Inc. (RCKT) was downgraded to D- from D on 11/8/2021 due to a large decline in the growth index, efficiency index and valuation index. EBIT declined 45.81% from -$34.05M to -$49.65M, net income declined 45.16% from -$34.53M to -$50.12M, and earnings per share declined from -$0.5475 to -$0.7852.
D
Sell
8/13/2019Upgraded
Rocket Pharmaceuticals, Inc. (RCKT) was upgraded to D from D- on 8/13/2019 due to an increase in the efficiency index, solvency index and growth index. The quick ratio increased from 9.56 to 17.09, total capital increased 32.41% from $222.44M to $294.53M, and debt to equity declined from 0.24 to 0.18.
Rocket Pharmaceuticals, Inc. (RCKT) was upgraded to D from D- on 8/13/2019 due to an increase in the efficiency index, solvency index and growth index. The quick ratio increased from 9.56 to 17.09, total capital increased 32.41% from $222.44M to $294.53M, and debt to equity declined from 0.24 to 0.18.
D
Sell
7/23/2019Downgrade
Rocket Pharmaceuticals, Inc. (RCKT) was downgraded to D- from D on 7/23/2019 due to a decline in the volatility index and total return index.
Rocket Pharmaceuticals, Inc. (RCKT) was downgraded to D- from D on 7/23/2019 due to a decline in the volatility index and total return index.
D
Sell
7/3/2019Upgraded
Rocket Pharmaceuticals, Inc. (RCKT) was upgraded to D from D- on 7/3/2019 due to an increase in the valuation index.
Rocket Pharmaceuticals, Inc. (RCKT) was upgraded to D from D- on 7/3/2019 due to an increase in the valuation index.
D
Sell
5/15/2019Downgrade
Rocket Pharmaceuticals, Inc. (RCKT) was downgraded to D- from D on 5/15/2019 due to a decline in the solvency index, valuation index and efficiency index. The quick ratio declined from 13.38 to 9.56, debt to equity increased from 0.21 to 0.26, and total capital declined 5.54% from $235.48M to $222.44M.
Rocket Pharmaceuticals, Inc. (RCKT) was downgraded to D- from D on 5/15/2019 due to a decline in the solvency index, valuation index and efficiency index. The quick ratio declined from 13.38 to 9.56, debt to equity increased from 0.21 to 0.26, and total capital declined 5.54% from $235.48M to $222.44M.
D
Sell
4/3/2019Upgraded
Rocket Pharmaceuticals, Inc. (RCKT) was upgraded to D from D- on 4/3/2019 due to a noticeable increase in the growth index, volatility index and solvency index. Debt to equity declined from 0.28 to 0.21, and the quick ratio increased from 12.38 to 13.38.
Rocket Pharmaceuticals, Inc. (RCKT) was upgraded to D from D- on 4/3/2019 due to a noticeable increase in the growth index, volatility index and solvency index. Debt to equity declined from 0.28 to 0.21, and the quick ratio increased from 12.38 to 13.38.
D
Sell
12/20/2018Downgrade
Rocket Pharmaceuticals, Inc. (RCKT) was downgraded to D- from D on 12/20/2018 due to a significant decline in the volatility index, total return index and efficiency index. Total capital declined 6.43% from $196.92M to $184.25M, and net income declined 2.04% from -$15.77M to -$16.09M.
Rocket Pharmaceuticals, Inc. (RCKT) was downgraded to D- from D on 12/20/2018 due to a significant decline in the volatility index, total return index and efficiency index. Total capital declined 6.43% from $196.92M to $184.25M, and net income declined 2.04% from -$15.77M to -$16.09M.
D
Sell
9/13/2018Upgraded
Rocket Pharmaceuticals, Inc. (RCKT) was upgraded to D from E+ on 9/13/2018 due to an increase in the efficiency index, growth index and total return index. Operating cash flow increased 16.06% from -$11.6M to -$9.74M, and earnings per share increased from -$0.4246 to -$0.3993.
Rocket Pharmaceuticals, Inc. (RCKT) was upgraded to D from E+ on 9/13/2018 due to an increase in the efficiency index, growth index and total return index. Operating cash flow increased 16.06% from -$11.6M to -$9.74M, and earnings per share increased from -$0.4246 to -$0.3993.
E
Sell
7/2/2018Upgraded
Rocket Pharmaceuticals, Inc. (RCKT) was upgraded to E+ from E on 7/2/2018 due to a large increase in the total return index, solvency index and growth index. The quick ratio increased from 4.01 to 24.9, and earnings per share increased from -$74.6135 to -$0.4246.
Rocket Pharmaceuticals, Inc. (RCKT) was upgraded to E+ from E on 7/2/2018 due to a large increase in the total return index, solvency index and growth index. The quick ratio increased from 4.01 to 24.9, and earnings per share increased from -$74.6135 to -$0.4246.
E
Sell
4/3/2018None
Rocket Pharmaceuticals, Inc. (RCKT) was downgraded to E from U on 04/03/2018.
Rocket Pharmaceuticals, Inc. (RCKT) was downgraded to E from U on 04/03/2018.
NASDAQ
03/20/2025 4:00PM Eastern
Quotes delayed
